Skip to main content

Advertisement

Table 1 Registries on severe asthma currently available in USA and Europe

From: SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma

Registry (reference) Country No. of centers Study population Outcomes
TENOR [8, 9] USA 283 4.756 Natural history of SA
BSAR [10] Belgium 9 350 Definition of clinical phenotypes in SA
Spanish Multi-Centers Registry [11] Spain 30 266 Omalizumab efficacy
Spanish Multi-Centers Registry [12] Spain 30 295 Omalizumab efficacy
NEONET [13] Italy 9 112 Omalizumab efficacy and safety
ARRISA [14] UK 29 Primary care practices 911 Impact of the network on exacerbation
BTS Severe Refractory Asthma Registry [15] UK 4 382 Phenotype characterization, standardized assessment
BTS Severe Refractory Asthma Registry [16] UK 4 349 Three years follow up
BTS Severe Refractory Asthma Registry [17] UK 4 349 Phenotype stability over time
BTS Severe Refractory Asthma Registry [18] UK 7 516 Economic analysis of SA
BTS Severe Refractory Asthma Registry [19] UK 7 808 Comorbidity due to the use of systemic steroid
  1. TENOR The epidemiology and natural history of asthma:outcomes and treatment regimens, BSAR Belgian Severe Asthma Registry, NEONET Italian North-East Omalizumab Network, ARRISA at risk register in severe asthma, BTS British Thoracic Society